The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The community screening programme charts an effective, affordable framework for TB control in the Canadian province of ...

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of ...

Oak Hill Bio and Chiesi have enrolled the first European patient in a Phase IIb study for OHB-607, to prevent BPD in infants.

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.